Intellia Therapeutics Inc (NASDAQ:NTLA) Receives $26.36 Consensus PT from Analysts

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have earned an average recommendation of “Hold” from the fourteen brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $26.36.

NTLA has been the topic of several analyst reports. Robert W. Baird initiated coverage on shares of Intellia Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $23.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Roth Capital started coverage on Intellia Therapeutics in a research report on Monday, June 10th. They issued a “neutral” rating and a $16.00 target price on the stock. Finally, Zacks Investment Research lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th.

Shares of NTLA stock traded down $0.21 during trading on Wednesday, hitting $13.63. 402,161 shares of the stock traded hands, compared to its average volume of 476,648. The firm has a market capitalization of $676.43 million, a P/E ratio of -6.88 and a beta of 2.71. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.99 and a quick ratio of 7.99. The firm’s fifty day moving average price is $16.58 and its 200-day moving average price is $16.02. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. The firm had revenue of $11.10 million for the quarter, compared to analyst estimates of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The business’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.52) EPS. As a group, equities research analysts expect that Intellia Therapeutics will post -2.29 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Benjamin Edwards Inc. raised its position in Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock valued at $28,000 after purchasing an additional 640 shares during the period. Tortoise Investment Management LLC grew its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after acquiring an additional 3,043 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after acquiring an additional 3,069 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Intellia Therapeutics in the second quarter worth $64,000. 80.96% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Article: Why Net Income is Important to Investors

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.